About The Institute
The Institute, a 501(c)(6) non-profit corporation, is an independent, private-sector, self-sustaining coalition. The Institute includes in its membership major employers and employer organizations, including leading American companies in the petrochemical, manufacturing, high technology, construction, pharmaceutical, hospitality, retail, and transportation industries, and many trade associations and community coalitions representing businesses of all sizes.
The Institute is active on legislative, legal, and regulatory issues at the federal, state, and local levels; has an extensive publications agenda; and has an active membership services program of action.
The Institute for a Drug-Free Workplace exists because there are serious threats to American employers and employees from drug abuse and its tragic human and economic costs. These threats include: (1) ignorance or complacence about the dangers of drug and alcohol abuse to the employer and its employees; (2) anti-drug testing legislation; (3) legal challenges; (4) regulations which unduly restrict employer programs; (5) misinformation or ignorance about drug testing; and (6) legalization campaigns.
Program of Action
The Institute for a Drug-Free Workplace educates employers, employees, legislators, public officials, the courts, the media, and the public at large about: (1) the dangers of substance abuse; (2) the impact of substance abuse on the workplace; (3) the most appropriate, effective, and legally acceptable means for employers to address substance abuse; (4) the rights and responsibilities of employers and employees; (5) legislative, regulatory, and legal developments; and (6) the role of employers in our national effort to combat substance abuse and its debilitating effects.
The Institute has continually grown each year in its membership, publications, and program of action. Executive Director, Mark A. de Bernardo, frequently advances the employer community’s position on workplace substance-abuse issues on behalf of the Institute. The Institute has testified more than 20 times at legislative and regulatory hearings on drug-testing issues; submitted written statements more than 50 times; and participated in more than 15 court cases as an amicus curiae (friend of the court). The Institute also has been directly involved with the development, consideration, and passage of legislation and regulations at both the state and Federal levels. For example, the Institute’s model state drug-testing law has been enacted, with minor changes, in five states.
For information about Institute publications and membership, please e-mail us at
email@example.com, or call (703)391-7222.